This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Tea Gunde, Ph.D.
Vice President, Discovery at Numab Therapeutics AG


Tea Gunde is Head of Discovery at Numab Therapeutics, a Swiss biotech company developing multiple immuno-oncology programs utilizing the versatile, multi-specific MATCH platform. Prior to joining Numab, Tea headed the pharmacokinetics & pharmacodynamics unit at ESBATech. She specialized in the discovery and preclinical development of therapeutic (bi-specific and multi-specific) antibodies for cancer immunotherapy. Tea led preclinical discovery and development projects in the field of ophthalmology and immuno-oncology and was instrumental in the discovery and the pre-clinical development of BEOVU®. In addition, she contributed to preclinical development of NM21-1480, an anti-PD-L1x4-1BBxSA scMATCH3 currently in active clinical development. Tea holds an MSc in Molecular Biology and Immunology from the University of Zurich, and a PhD in Molecular Biology from the University of Zurich.

Agenda Sessions

  • Advancement of MATCH Antibodies to Clinical-stage: Novel Therapeutics with Tumor Targeted Immunomodulatory Functions and the Potential for Favorable Benefit-risk Profiles